{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:08:24Z","timestamp":1785276504661,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40265-023-01969-3","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T15:02:12Z","timestamp":1700060532000},"page":"1699-1707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor\/Tezacaftor\/Ivacaftor, Utilizing the Updated RUCAM"],"prefix":"10.1007","volume":"83","author":[{"given":"Daniel","family":"Tewkesbury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowland","family":"Bright-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyn","family":"Cratchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Piper","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varinder","family":"Athwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-4431","authenticated-orcid":false,"given":"Peter J.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"issue":"19","key":"1969_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"10212","key":"1969_CR2","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20138.","journal-title":"Lancet"},{"issue":"9","key":"1969_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","volume":"385","author":"PJ Barry","year":"2021","unstructured":"Barry PJ, et al. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021;385(9):815\u201325.","journal-title":"N Engl J Med"},{"key":"1969_CR4","volume":"34","author":"M Salehi","year":"2021","unstructured":"Salehi M, et al. Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio). Respir Med Case Rep. 2021;34: 101553.","journal-title":"Respir Med Case Rep"},{"issue":"2","key":"1969_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","volume":"22","author":"DH Tewkesbury","year":"2023","unstructured":"Tewkesbury DH, et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre. J Cyst Fibros. 2023;22(2):256\u201362.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"1969_CR6","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jcf.2017.09.006","volume":"17","author":"AT Trimble","year":"2018","unstructured":"Trimble AT, Donaldson SH. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. J Cyst Fibros. 2018;17(2):e13\u20136.","journal-title":"J Cyst Fibros"},{"key":"1969_CR7","unstructured":"NHS England. Commissioning statement: Ivacaftor, tezacaftor\/ivacaftor, lumacaftor\/ivacaftor and elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis. 2023. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/03\/commissioning-statement-cf-modulator-therapies-for-cystic-fibrosis-updated-may-2023.pdf. Accessed 19 Sep 2023."},{"issue":"1","key":"1969_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1969_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jcf.2020.05.002","volume":"19","author":"W Karnsakul","year":"2020","unstructured":"Karnsakul W, et al. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease. J Cyst Fibros. 2020;19(4):546\u201352.","journal-title":"J Cyst Fibros"},{"key":"1969_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101547","volume":"51","author":"YT Cao","year":"2022","unstructured":"Cao YT, et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. EClinicalMedicine. 2022;51: 101547.","journal-title":"EClinicalMedicine."},{"key":"1969_CR11","unstructured":"Centers for Disease Control and Prevention. Binge Drinking. 2022. https:\/\/www.cdc.gov\/alcohol\/fact-sheets\/binge-drinking.htm#:~:text=Binge%20drinking%20is%20the%20most,use%20in%20the%20United%20States.&text=Binge%20drinking%20is%20defined%20as,are%20not%20dependent%20on%20alcohol. Accessed 10 Sep 2022."},{"issue":"3","key":"1969_CR12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.japh.2023.02.015","volume":"63","author":"M Wood","year":"2023","unstructured":"Wood M, et al. Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor. J Am Pharm Assoc (2003). 2023;63(3):920\u20134.","journal-title":"J Am Pharm Assoc (2003)."},{"issue":"2","key":"1969_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, et al. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):265\u201371.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"1969_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.bpg.2010.08.003","volume":"24","author":"U Herrmann","year":"2010","unstructured":"Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24(5):585\u201392.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1969_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.04.023","author":"P Tachtatzis","year":"2023","unstructured":"Tachtatzis P, et al. Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and liver transplant. J Cyst Fibros. 2023. https:\/\/doi.org\/10.1016\/j.jcf.2023.04.023.","journal-title":"J Cyst Fibros"},{"key":"1969_CR16","doi-asserted-by":"publisher","unstructured":"Sharma P, Giddings OK. Acute Liver Failure in a Patient with Cystic Fibrosis Taking Triple Combination Modulator. 2021. https:\/\/doi.org\/10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A2113. Accessed 20 May 2022.","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A2113"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01969-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:18:10Z","timestamp":1703002690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01969-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":16,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1969"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01969-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"assertion":[{"value":"25 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Daniel Tewkesbury, Rowland Bright-Thomas, Alyn Cratchley, Karen Piper Hanley and Judith Wyatt have no conflicts of interest to declare. Andrew M. Jones has accepted speaker fees from Vertex pharmaceuticals; Varinder Athwal has accepted speaking fees and honoraria from Vertex pharmaceuticals and Roche diagnostics; and Peter J. Barry has accepted speaking fees and honoraria from Vertex pharmaceuticals and advisory board fees from INSMED.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated during this study. All clinical data analysed are included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This work received approval from the institutional information governance department.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written consent was obtained from individuals to publish and share liver histology images.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"DT<b>:<\/b> conceptualization, methodology, formal analysis, investigation, writing\u2014original draft, visualization. VA: conceptualization, supervision, writing\u2014review and editing. RBT: conceptualization, writing\u2014review and editing, supervision. AC: formal analysis, writing\u2014review and editing. KPH: supervision, writing\u2014review and editing. AJ: Conceptualization, writing\u2014review and editing, supervision. JW: formal analysis, writing\u2014review and editing. PB: conceptualization, writing\u2014review and editing, supervision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}